Factor Product Utilization and Health Outcomes in Patients With Hemophilia

Hemophilia A, Congenital Clinical Trial

Official title:
Factor Product Utilization and Health Outcomes in Patients With Hemophilia A and B in Canada: An Observational Study of Real-world Outcomes

Status Completed

Clinical Trial Summary

Recombinant factor VIII Fc (rFVIIIFc) and recombinant factor IX Fc (rFIXFc) are extended half-life coagulation factors approved by Health Canada in 2014 for the treatment of severe hemophilia A and B, respectively. The objectives of this observational study is to describe the change in annual factor consumption, clinical and patient-reported outcomes for patients who switch from recombinant factor VIII (rFVIII) and recombinant factor IX (rFIX) to rFVIIIFc/ rFIXFc in Canada, and to explore clinicians' and patients' reasons for switching or not switching.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02796222
Study type	Observational
Source	University of British Columbia
Contact
Status	Completed
Phase
Start date	April 2016
Completion date	April 26, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02830477` - Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Terminated	`NCT03095287` - Alphanate in Immune Tolerance Induction Therapy	Phase 2
Completed	`NCT03034044` - Post-Marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled Syringe
Completed	`NCT02253693` - Exploratory Pilot Study of Physical Activity Monitoring in Adult Patients With Haemophilia A by Means of Accelerometry	N/A